- Benzinga•3 days ago
PTC Therapeutics, Inc. (NASDAQ: PTCT ) shares popped Thursday morning, following a note from Credit Suisse that said the stock could trade up by more than 500 percent.. The predicted activity will depend ...
- Zacks•6 days ago
Investors in PTC Therapeutics, Inc. (PTCT) need to pay close attention to the stock based on moves in the options market lately.
- PR Newswire•11 days ago
SOUTH PLAINFIELD, N.J., Feb. 8, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced the third annual STRIVE (Strategies to Realize Innovation, Vision and Empowerment) grant award program for Duchenne muscular dystrophy (DMD). STRIVE provides funds to patient advocacy organizations to develop unique and collaborative programs that will make meaningful contributions to the rare disease community by increasing awareness, diagnosis, education or fostering development of future patient advocates. The patients and organizations have been at the heart of everything we do at PTC and it is particularly rewarding to support programs to further develop new programs to support the Duchenne community around the world," said Mary Frances Harmon, Global Head of Patient Advocacy at PTC.
PTCT : Summary for PTC Therapeutics, Inc. - Yahoo Finance
PTC Therapeutics, Inc. (PTCT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||13.95 x 800|
|Ask||15.69 x 100|
|Day's Range||13.50 - 14.41|
|52 Week Range||4.03 - 29.98|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.89|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|